Interleukin-1 Receptor Antagonism as Adjunct Therapy for Heart Failure Patients with Left Ventricular Assist Devices.
Aaron H HealyMegan BowenStephen H McKellarAntigone KoliopoulouStavros G DrakosCraig H SelzmanPublished in: ASAIO journal (American Society for Artificial Internal Organs : 1992) (2021)
While left ventricular assist devices (LVAD) successfully unload the failing ventricle, most hearts do not regain sufficient function to allow for device explantation. Herein, we report a pilot series of LVAD patients treated with interleukin-1 receptor antagonism as a biologic adjuvant that safely and effectively treated inflammation so as to create a milieu whereby the heart could functionally improve. This pilot study sets the stage for a more rigorous, controlled trial of interleukin-1 receptor antagonism in treating heart failure and promoting myocardial recovery in patients supported by LVADs.
Keyphrases
- left ventricular
- heart failure
- ejection fraction
- aortic stenosis
- end stage renal disease
- mitral valve
- cardiac resynchronization therapy
- hypertrophic cardiomyopathy
- newly diagnosed
- rheumatoid arthritis
- atrial fibrillation
- chronic kidney disease
- acute myocardial infarction
- oxidative stress
- peritoneal dialysis
- study protocol
- clinical trial
- randomized controlled trial
- binding protein
- prognostic factors
- transcatheter aortic valve replacement
- pulmonary artery
- bariatric surgery
- left ventricular assist device
- acute coronary syndrome
- pulmonary arterial hypertension
- coronary artery disease